肥酸与纤维酸作为初级胆道胆道炎的二线疗法:系统审查和元分析
Eliabe S Abreu1, Pedro Henrique Reginato2, Jorge Ferreira Jasmineiro Pitanga3
1Division of Gastroenterology & Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. abreu.eliabe@mayo.edu.
Digestive diseases and sciences
|April 19, 2025
概括
纤维酸在改善初级胆汁胆道炎 (PBC) 患者的肝脏生化学方面显示出比肥酸 (OCA) 更大的有效性,这些患者对乌尔索多氧酸 (UDCA) 的反应不足最佳. 纤维素显著降低性酸酶 (ALP),并增加治疗反应率.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 原发性胆道胆炎 (PBC) 影响了许多对乌尔索氧胆酸 (UDCA) 反应不足的患者.
- 第二线疗法对于管理低于最佳生物化学标记的PBC患者至关重要.
研究的目的:
- 为了比较纤维酸与肥酸 (OCA) 的疗效,作为PBC的附加二线疗法.
- 为了确定纤维酸或OCA在不完全UDCA反应的患者中是否提供更好的结果.
主要方法:
- 在2024年5月6日之前对Embase,MEDLINE和Cochrane CENTRAL的系统文献搜索.
- 综合分析了4项涉及883名患者的研究,以评估肝脏生物化学变化和反应率.
- 用连续数据的平均差异 (MD) 和二进制数据的几率比率 (OR) 分析的结果.
主要成果:
- 与OCA相比,纤维酸证明了性酸酶 (ALP) 水平的优越降低.
- 纤维化剂患者的ALP正常化率更高,并且满足了更多的反应标准 (巴塞罗那,POISE,巴黎II).
- 纤维酸和OCA组之间的平均胆红素水平相似.
结论:
- 纤维酸似乎比OCA更有效地改善ALP,并在不完全UDCA反应的PBC患者中达到治疗反应标准.
- 纤维酸为这种患者群体提供了有前途的二线治疗选择.
相关概念视频
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
49
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
49
01:17Chronic Bowel Disorders: Introduction
298
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
298
01:29Chronic Pancreatitis II: Collaborative Care
46
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
46
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
01:30Acute Pancreatitis II: Clinical Manifestations and Management
65
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
65